Free Trial

Belite Bio (BLTE) News Today

Belite Bio logo
$62.59 -0.37 (-0.59%)
(As of 10:39 AM ET)
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Shares Gap Up - Here's What Happened
Belite Bio (NASDAQ:BLTE) Shares Gap Up - What's Next?
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Shares Down 3.4% - Time to Sell?
Belite Bio (NASDAQ:BLTE) Shares Down 3.4% - Here's Why
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Shares Down 4.5% - Here's What Happened
Belite Bio (NASDAQ:BLTE) Trading Down 4.5% - Here's What Happened
Belite Bio: Interesting Science, But Quite A Few Worries
Belite Bio, Inc stock logo
Cantor Fitzgerald Predicts Weaker Earnings for Belite Bio
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities researchers at Cantor Fitzgerald reduced their FY2024 earnings per share estimates for shares of Belite Bio in a research note issued on Wednesday, November 13th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will post earni
Belite Bio, Inc stock logo
FY2024 EPS Estimates for Belite Bio Lowered by HC Wainwright
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Investment analysts at HC Wainwright reduced their FY2024 earnings estimates for shares of Belite Bio in a research report issued to clients and investors on Wednesday, November 13th. HC Wainwright analyst Y. Chen now expects that the company will pos
Belite Bio, Inc stock logo
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Decreases By 13.5%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a large drop in short interest in October. As of October 31st, there was short interest totalling 234,000 shares, a drop of 13.5% from the October 15th total of 270,600 shares. Based on an average trading volume of 52,000 shares, the days-to-cover ratio is presently 4.5 days.
Belite Bio price target raised to $110 from $60 at Maxim
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Given New $110.00 Price Target at Maxim Group
Maxim Group raised their price objective on shares of Belite Bio from $60.00 to $110.00 and gave the company a "buy" rating in a research note on Friday.
Belite Bio Advances in Retinal Disease Trials
Belite Bio price target raised to $100 from $60 at H.C. Wainwright
Insights into Belite Bio's Upcoming Earnings
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
Belite Bio, Inc stock logo
Belite Bio (BLTE) Scheduled to Post Earnings on Tuesday
Belite Bio (NASDAQ:BLTE) will be releasing earnings after the market closes on Tuesday, November 12, Zacks reports.
Belite Bio Offers New Warrant Opportunities to Investors
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Sees Strong Trading Volume - Here's What Happened
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase - Still a Buy?
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Reaches New 12-Month High - What's Next?
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High - Still a Buy?
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Stock Price Up 4% - Should You Buy?
Belite Bio (NASDAQ:BLTE) Stock Price Up 4% - Time to Buy?
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High - Here's What Happened
Belite Bio (NASDAQ:BLTE) Reaches New 1-Year High - Time to Buy?
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Hits New 1-Year High at $50.69
Belite Bio (NASDAQ:BLTE) Sets New 12-Month High at $50.69
Belite Bio, Inc stock logo
Armistice Capital LLC Makes New $6.76 Million Investment in Belite Bio, Inc (NASDAQ:BLTE)
Armistice Capital LLC purchased a new position in shares of Belite Bio, Inc (NASDAQ:BLTE - Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 148,000 shares of the company's stock, valued at approxi
Belite Bio, Inc stock logo
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Declines By 5.1%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the recipient of a significant decline in short interest in the month of August. As of August 31st, there was short interest totalling 270,200 shares, a decline of 5.1% from the August 15th total of 284,800 shares. Based on an average daily trading volume, of 44,000 shares, the short-interest ratio is currently 6.1 days.
Belite Bio, Inc stock logo
Belite Bio's (BLTE) "Buy" Rating Reiterated at HC Wainwright
HC Wainwright restated a "buy" rating and set a $60.00 price objective on shares of Belite Bio in a report on Thursday.
Belite Bio Inc (D01.DU)
Belite Bio Appoints Hendrik Scholl As Chief Medical Officer
Belite Bio, Inc stock logo
Belite Bio, Inc (NASDAQ:BLTE) Sees Significant Decrease in Short Interest
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) saw a significant drop in short interest during the month of August. As of August 15th, there was short interest totalling 284,800 shares, a drop of 9.6% from the July 31st total of 315,200 shares. Based on an average daily trading volume, of 50,200 shares, the days-to-cover ratio is presently 5.7 days.
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Sees Unusually-High Trading Volume
Belite Bio (NASDAQ:BLTE) Sees Large Volume Increase
Belite Bio, Inc stock logo
Short Interest in Belite Bio, Inc (NASDAQ:BLTE) Expands By 10.7%
Belite Bio, Inc (NASDAQ:BLTE - Get Free Report) was the target of a significant increase in short interest in the month of July. As of July 31st, there was short interest totalling 315,200 shares, an increase of 10.7% from the July 15th total of 284,700 shares. Based on an average daily trading volume, of 53,800 shares, the short-interest ratio is presently 5.9 days.
Belite Bio, Inc stock logo
Belite Bio (NASDAQ:BLTE) Trading Down 1.8%
Belite Bio (NASDAQ:BLTE) Stock Price Down 1.8%
Belite Bio, Inc stock logo
FY2024 EPS Estimates for Belite Bio, Inc Lowered by Analyst (NASDAQ:BLTE)
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Equities research analysts at Cantor Fitzgerald reduced their FY2024 earnings per share (EPS) estimates for Belite Bio in a report issued on Tuesday, August 13th. Cantor Fitzgerald analyst J. Kim now forecasts that the company will earn ($1.17) per sh
Belite Bio, Inc stock logo
Q1 2025 Earnings Forecast for Belite Bio, Inc (NASDAQ:BLTE) Issued By HC Wainwright
Belite Bio, Inc (NASDAQ:BLTE - Free Report) - Research analysts at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for shares of Belite Bio in a report issued on Tuesday, August 13th. HC Wainwright analyst Y. Chen expects that the company will post earnings of ($0.29) per sh
Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.

Nvidia’s Bold Move: Tackling Tech’s $1 Trillion Crisis (Ad)

Taiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as 4,744%. Now, if you’re like everybody else, you want to know what Nvidia’s doing next … and who they’re going to partner with …

Find out details on these three critical Nvidia partners immediately.

BLTE Media Mentions By Week

BLTE Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

BLTE
News Sentiment

-0.55

0.54

Average
Medical
News Sentiment

BLTE News Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

BLTE Articles
This Week

0

2

BLTE Articles
Average Week

Get Belite Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for BLTE and its competitors with MarketBeat's FREE daily newsletter.


Related Companies and Tools


This page (NASDAQ:BLTE) was last updated on 12/19/2024 by MarketBeat.com Staff
From Our Partners